From: Serum lipocalin-2 levels positively correlate with coronary artery disease and metabolic syndrome
Variables | Non-CAD | CAD | ||||
---|---|---|---|---|---|---|
Total | Men | Women | Total | Men | Women | |
N | 73 | 38 | 35 | 188 | 131 | 57 |
Age (years) | 63.6 ± 9.4 | 62.1 ± 9.7 | 65.2 ± 8.8 | 66.8 ± 9.5a | 65.7 ± 9.9b | 69.3 ± 8.0c |
CSI | 0 (0–1) | 0 (0–1) | 0 (0–1) | 9 (5–14)aa | 10 (5–14)bb | 8 (4–14)cc |
BMI (kg/m2) | 25.5 ± 3.7 | 25.4 ± 4.1 | 25.6 ± 3.4 | 24.4 ± 3.1a | 24.7 ± 3.1 | 23.9 ± 3.0c |
W (cm) | 90.7 ± 10.8 | 92.7 ± 11.9 | 88.5 ± 9.0 | 90.3 ± 8.8 | 91.7 ± 8.5 | 87.3 ± 8.7 |
SBP (mmHg) | 130 (120–150) | 130 (120–150) | 130 (120–145) | 133 (120–150) | 130 (120–147) | 140 (128–150) |
DBP (mmHg) | 80 (70–87) | 80 (70–88) | 80 (70–86) | 80 (70–84) | 80 (70–84) | 75 (70–82) |
FPG (mmol/L) | 5.38 (5.07-6.17) | 5.64 (5.12-6.23) | 5.31 (5.00-5.96) | 5.46 (5.04-6.57) | 5.44 (5.04-6.41) | 5.59 (4.99-7.64) |
2hPG (mmol/L) | 8.17 (6.27-9.97) | 9.12 (6.79-10.55) | 7.17 (5.27-9.29) | 8.76 (6.66-11.92) | 8.77 (6.71-12.16) | 8.67 (6.49-11.72) |
HbA1c (%) | 6.2 (5.7-6.5) | 6.2 (5.6-6.5) | 6.2 (5.7-6.4) | 6.2 (5.8-6.9) | 6.2 (5.8-6.7) | 6.4 (5.8-7.2) |
HOMA-IR | 4.1 (2.9-5.9) | 3.9 (3.1-5.4) | 4.9 (2.8-6.0) | 4.0 (2.8-5.9) | 4.0 (2.7-5.6) | 4.3 (2.9-6.8) |
TC (mmol/L) | 4.53 ± 1.03 | 4.20 ± 0.95 | 4.90 ± 0.99 | 4.31 ± 1.10 | 4.17 ± 1.02 | 4.63 ± 1.20 |
TG (mmol/L) | 1.63 (1.04-2.30) | 1.62 (1.09-2.18) | 1.66 (0.88-2.44) | 1.51 (1.08-2.25) | 1.49 (1.04-2.14) | 1.57 (1.17-2.57) |
HDL-c (mmol/L) | 1.07 (0.88-1.37) | 0.97 (0.81-1.38) | 1.26 (1.06-1.37) | 1.02 (0.87-1.28) | 0.96 (0.85-1.16) | 1.19 (0.93-1.35) |
LDL-c (mmol/L) | 3.06 ± 0.86 | 2.85 ± 0.90 | 3.30 ± 0.76 | 2.90 ± 0.99 | 2.83 ± 0.93 | 3.08 ± 1.10 |
Serum adiponectin (ug/mL) | 7.8 (5.7-11.5) | 7.4 (5.0-10.5) | 8.9 (5.8-14.2) | 7.0 (4.8-11.1) | 6.5 (4.4-10.6) | 7.9 (6.1-13.0) |
UA (μmol/L) | 341.6 ± 85.2 | 383.0 ± 79.5 | 295.2 ± 66.1 | 342.0 ± 82.7 | 349.1 ± 78.1b | 325.7 ± 91.0 |
Scr (μmol/L) | 73.2 ± 18.4 | 83.2 ± 15.8 | 61.9 ± 14.2 | 78.0 ± 19.4 | 83.8 ± 17.1 | 64.5 ± 17.7 |
24hALB (mg/d) | 7.8 (4.9-17.1) | 8.5 (5.6-18.1) | 6.6 (3.4-15.3) | 7.0 (4.7-14.3) | 7.1 (4.6-12.9) | 6.7 (5.1-19.6) |
eGFR (mL/min/1.73 m2) | 92.6 ± 22.7 | 90.3 ± 19.7 | 95.2 ± 25.7 | 89.6 ± 22.3 | 89.2 ± 21.3 | 90.7 ± 24.9 |
CRP (mg/L) | 1.1 (0.4-3.1) | 1.0 (0.5-2.4) | 1.2 (0.4-3.1) | 1.1 (0.5-2.8) | 1.0 (0.5-2.8) | 1.2 (0.5-3.5) |
Neutrophils (×109/L) | 4.0 (3.1-4.7) | 4.1 (3.3-5.1) | 3.5 (2.6-4.5) | 3.9 (3.1-4.7) | 4.0 (3.3-4.7) | 3.4 (2.9-4.3) |
Smoking, n (%) | 26 (35.6) | 25 (65.8) | 1 (2.9) | 86 (45.7) | 85 (64.9) | 1 (1.8) |
CAD family history, n (%) | 33 (45.2) | 19 (50.0) | 14 (40.0) | 85 (45.2) | 57 (43.5) | 28 (49.1) |
Hypoglycemic therapy, n (%) | 11 (15.1) | 6 (15.8) | 5 (14.3) | 51 (27.1)a | 31 (23.7) | 20 (35.1)c |
Anti-hypertensive therapy, n (%) | 50 (68.5) | 30 (78.9) | 20 (57.1) | 128 (68.1) | 89 (67.9) | 39 (68.4) |
Lipid-lowering therapy, n (%) | 11 (15.1) | 6 (15.8) | 5 (14.3) | 62 (33.0)aa | 43 (32.8)b | 19 (33.3)c |